Cargando…

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation

The efficacy of sustained-release preparations of mesalazine as a remission maintenance treatment for Crohn's disease remains to be established. We aimed to examine the changes in compliance rate and clinical data 2 years after switching from mesalazine tablet to granule formulation at our faci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Satoshi, Ishida, Natsuki, Miyazu, Takahiro, Onoue, Shunya, Tani, Shinya, Yamade, Mihoko, Hamaya, Yasushi, Iwaizumi, Moriya, Osawa, Satoshi, Furuta, Takahisa, Sugimoto, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721736/ https://www.ncbi.nlm.nih.gov/pubmed/33288852 http://dx.doi.org/10.1038/s41598-020-78603-9

Ejemplares similares

Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
por: Ishida, Natsuki, et al.
Publicado: (2021)

Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
por: Ishida, Natsuki, et al.
Publicado: (2021)

Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study
por: Matsuura, Tomoharu, et al.
Publicado: (2023)

Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience
por: Ishida, Natsuki, et al.
Publicado: (2020)

C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission
por: Miyazu, Takahiro, et al.
Publicado: (2021)

Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
por: Tamura, Satoshi, et al.
Publicado: (2021)

Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
por: Ishida, Natsuki, et al.
Publicado: (2022)

Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2022)

Modified method of patency judgement using patency capsule prior to capsule endoscopy in clinical practice
por: Miyazu, Takahiro, et al.
Publicado: (2022)

Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study
por: Ishida, Natsuki, et al.
Publicado: (2021)

Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
por: Ishida, Natsuki, et al.
Publicado: (2020)

Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease
por: Ishida, Natsuki, et al.
Publicado: (2021)

Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study
por: Miyazu, Takahiro, et al.
Publicado: (2022)

The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2020)

Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2022)

Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
por: Ishida, Natsuki, et al.
Publicado: (2022)

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2020)

Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report
por: Ishida, Natsuki, et al.
Publicado: (2020)

Intrahepatic cholangiocarcinoma in patients with primary sclerosing cholangitis and ulcerative colitis: Two case reports
por: Miyazu, Takahiro, et al.
Publicado: (2023)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission
por: Takano, Ryosuke, et al.
Publicado: (2018)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma
por: Mori, Taiki, et al.
Publicado: (2018)

DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection
por: Sugiyama, Tomohiro, et al.
Publicado: (2020)

High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2018)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study
por: Kaneko, Masanao, et al.
Publicado: (2023)

Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
por: Osawa, Satoshi, et al.
Publicado: (2009)

MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells
por: Suzuki, Satoshi, et al.
Publicado: (2017)

Decompressive laparotomy for abdominal compartment syndrome resulting from severe acute pancreatitis: a case report
por: Ikeda, Shinya, et al.
Publicado: (2019)

Regulatory filing strategy for generic mesalazine modified release formulations
por: Gupta, Sandeep K.
Publicado: (2011)

Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast
por: Knorr, Barbara, et al.
Publicado: (2010)

Soft-Chewable Paracetamol Tablets by Melt Granulation Method: Formulation and Characterization
por: Sabere, Awis Sukarni Mohmad, et al.
Publicado: (2021)

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Formulation and Evaluation of Controlled-Release Tablet of Zolpidem Tartrate by Melt Granulation Technique
por: Prajapati, Shailesh T., et al.
Publicado: (2011)

Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations
por: Martir, J., et al.
Publicado: (2020)

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gtjel3shi32kh5psr15lpfnn45